Treatment of hyperhomocysteinemia with folic acid reduces oxidative stress in renal transplant recipients

Transplantation. 2002 Feb 27;73(4):663-5. doi: 10.1097/00007890-200202270-00034.

Abstract

Background: We conducted a prospective, uncontrolled, open study to assess the relationship between homocysteine (tHcy) and oxidative stress in chronic, stable, renal transplant recipients (RTR).

Methods: Included in the study were 17 chronic, stable RTR. All the patients received folic acid (5 mg/day). tHcy and total antioxidant capacity (TAOC) were measured before and at the end of the study period.

Results: Mean tHcy concentration was 26+/-10 micromol/L. tHcy significantly decreased during the study period (26+/-10 vs. 18+/-7 micromol/L; P<0.001). There was a significant inverse relationship between TAOC and tHcy (r= -0.33; P=0.01). TAOC significantly increased during the study period (1.49+/-0.23-1.78+/-0.6; P<0.001). There was an inverse relationship between the variation in tHcy and the variation in TAOC (r= -0.44; P=0.01).

Conclusion: Our results demonstrate that hyperhomocysteinemia contributed to increased oxidative stress in RTR. tHcy-lowering treatment with folic acid may lower oxidative stress.

Publication types

  • Clinical Trial

MeSH terms

  • Adult
  • Antioxidants / therapeutic use*
  • Fasting
  • Female
  • Folic Acid / blood
  • Folic Acid / therapeutic use*
  • Homocysteine / blood
  • Humans
  • Hyperhomocysteinemia / drug therapy*
  • Kidney Transplantation / physiology*
  • Male
  • Oxidative Stress / drug effects*
  • Postoperative Complications / drug therapy*
  • Time Factors

Substances

  • Antioxidants
  • Homocysteine
  • Folic Acid